HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Breen, S. L. Articles by Porter, A. T. Search for Related Content PubMed PubMed Citation Articles by Breen, S. L. Articles by Porter, A. T.

Dose Estimation in Strontium-89 Radiotherapy of Metastatic Prostatic Carcinoma

Stephen L. Breen^*, J. E. Powe and A. T. Porter

Departments of Medical Biophysics, Diagnostic Radiology & Nuclear Medicine, and Oncology, University of Western Ontario
Department of Nuclear Medicine, Victoria Hospital and London Regional Cancer Centre, London, Ontario, Canada

Correspondence: For reprints contact: Stephen L. Breen, MSc, Physics Department, London Regional Cancer Centre, 790 Comissioners Rd. E., London, Ontario, Canada N6A 4L6.

ABSTRACT

Strontium-89 radiotherapy is becoming an important treatment in the palliation of bone pain from osteoblastic metastases. The absorbed dose delivered to bone metastases during ⁸⁹Sr radiotherapy has been estimated in four patients with metastatic prostatic carcinoma. Patients were injected with a tracer dose of ⁸⁹Sr-chloride. Blood and urine samples were obtained during the week following injection. Strontium-85 scintigrams of metastases and normal bone were obtained up to 8 wk postinjection. Half of the patients showed elevated whole-body retention; plasma-strontium concentrations were decreased from normal values. Uptake of strontium in metastases was 2–25 times that in normal bone but rates of washout of strontium from metastases were similar to those from normal bone. Absorbed doses delivered in infinite time to the metastases by ⁸⁹Sr ranged from 21 ± 4 to 231 ± 56 cGy/MBq with a median value of 68 cGy/MBq. Doses to red marrow were less by a factor of 2 to 50. These absorbed doses are sufficiently large to be expected to produce a therapeutic benefit.

FOOTNOTES

^* Current Addresses: Physics Department, London Regional Cancer Centre, London, Ontario, Canada.

Department of Radiation Oncology, Wayne State University and Harper Hospital, Detroit, Michigan.

This article has been cited by other articles:

				O. S. Bruland, S. Nilsson, D. R. Fisher, and R. H. Larsen High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the {alpha}-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? Clin. Cancer Res., October 15, 2006; 12(20): 6250s - 6257s. [Abstract] [Full Text] [PDF]

				K. Liepe, R. Runge, and J. Kotzerke Systemic radionuclide therapy in pain palliation American Journal of Hospice and Palliative Medicine, November 1, 2005; 22(6): 457 - 464. [Abstract] [PDF]

				V. J. Lewington Bone-Seeking Radionuclides For Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 38S - 47S. [Abstract] [Full Text] [PDF]

				H. Smith, A. Navani, and S. M. Fishman Radiopharmaceuticals for palliation of painful osseous metastases American Journal of Hospice and Palliative Medicine, July 1, 2004; 21(4): 303 - 313. [Abstract] [PDF]

				A. N. Serafini Therapy of Metastatic Bone Pain J. Nucl. Med., June 1, 2001; 42(6): 895 - 906. [Abstract] [Full Text] [PDF]

				O. Israel, Z. Keidar, R. Rubinov, G. Iosilevski, A. Frenkel, A. Kuten, L. Betman, G. M. Kolodny, D. Yarnitsky, and D. Front Quantitative Bone Single-Photon Emission Computed Tomography for Prediction of Pain Relief in Metastatic Bone Disease Treated With Rhenium-186 Etidronate J. Clin. Oncol., July 14, 2000; 18(14): 2747 - 2754. [Abstract] [Full Text] [PDF]